Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Cancer Research

Background:

• Ruthenium(II)-arene complexes show promise in cancer therapy.
• Perfluoroalkyl-modified ligands can enhance selectivity and efficacy.
• Previous studies identified a selective ruthenium(II)-arene complex, [Ru(η(6)-p-cymene)Cl2(1H,1H,2H,2H-perfluorodecyl-3-(pyridin-3-yl)propanoate)].

Purpose of the Study:

• To design and synthesize novel ruthenium(II)-arene complexes.
• To modulate steric bulk and aquation kinetics through ligand modification.
• To evaluate the anticancer potential of these new derivatives.

Main Methods:

• Synthesis of structurally related ruthenium(II)-arene complexes.
• In vitro evaluation: cytotoxicity and cell migration assays.
• In vivo evaluation using the chicken chorioallantoic membrane model.

Main Results:

• The synthesized compounds exhibited potent antivascular effects.
• Structural modifications influenced the compounds' properties.
• The derivatives demonstrated significant anticancer activity in both in vitro and in vivo models.

Conclusions:

• The novel ruthenium(II)-arene complexes possess potent antivascular and anticancer properties.
• Ligand modification is a viable strategy to optimize the efficacy of these complexes.
• These compounds represent promising candidates for further development as anticancer agents.